PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
34.37%
Net income growth at 50-75% of AVXL's 58.15%. Martin Whitman would worry about lagging competitiveness unless expansions are planned.
0.63%
D&A growth well above AVXL's 0.22%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
-79.79%
Both cut yoy SBC, with AVXL at -34.98%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-121.40%
Both reduce yoy usage, with AVXL at -41.85%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-200.00%
Both negative yoy AP, with AVXL at -100.00%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-91.42%
Negative yoy usage while AVXL is 2145.18%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
2.52%
Lower 'other non-cash' growth vs. AVXL's 204.38%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-18.12%
Negative yoy CFO while AVXL is 89.51%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both yoy lines negative, with AVXL at -60.18%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.